Quarterly report pursuant to Section 13 or 15(d)

REVENUES - Disaggregated (Details)

v3.24.1.u1
REVENUES - Disaggregated (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total revenues $ 29,534 $ 26,070
Gross product sales    
Disaggregation of Revenue [Line Items]    
Total revenues 38,426 33,198
Discounts and allowances    
Disaggregation of Revenue [Line Items]    
Total revenues (12,423) (9,453)
Product sales, net    
Disaggregation of Revenue [Line Items]    
Total revenues 26,003 23,745
Delivery of drug supplies, royalty and others    
Disaggregation of Revenue [Line Items]    
Total revenues 3,531 2,325
Revenues from collaborations    
Disaggregation of Revenue [Line Items]    
Total revenues $ 3,531 $ 2,325